 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Seo Jung-jin, chairman of Celltrion Group, hinted at the possibility of listing Celltrion Holdings, the holding company, after the ongoing merger of the three listed companies. The plan is to complete the merger of the three companies first and review it if necessary.
On the 24th, Seo Jeong-jin, chairman of the Celltrion Group, said at an online meeting with investors, "We will consider listing Celltrion Holdings if necessary after the current merger.” There has never been a sale of the company's stake, and there are no plans to sell it in the future."
Celltrion Group began the merger process on the 17th with the approval of Celltrion and Celltrion Healthcare. Celltrion absorbs and merges Celltrion Healthcare. The expected effect of the merger is to improve cost competitiveness through unification of development and sales and to secure large-scale investment resources for the development of new drugs and new modality. In addition, as financial standards through simplification of transaction structure become clearer, it aims to increase investor confidence by enhancing transparency.
Once the merger between the two companies is completed by the end of this year, the company will begin the second phase of the merger process within six months, and integrated Celltrion (Celltrion + Celltrion Healthcare) will merge with Celltrion Pharmaceutical to complete the merger of the three companies. Through this, the company aims to become a company that encompasses new drugs beyond biosimilars and expand sales to 12 trillion won by 2030.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
